Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

microRNA-223 Expression during Flares in Patients with Generalized Pustular Psoriasis Is Regulated by Spesolimab Treatment

29 Aug 2025

Abstract excerpt

Generalized pustular psoriasis (GPP) is a systemic, neutrophilic inflammatory disease characterized by chronic symptoms and periods of flaring. GPP is associated with significant morbidity, and GPP flares are potentially life threatening if left untreated (Puig et al, 2023). GPP pathogenesis involves dysregulated IL-36 signaling, thus highlighting IL-36 pathway blockade as a promising therapeutic target (Hawkes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to IL-33, ST2, and ILC Pathways
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40885519
DOI: 10.1016/j.jid.2025.08.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

microRNA-223 Expression during Flares in Patients with Generalized Pustular Psoriasis Is Regulated by Spesolimab TreatmentPMID 40885519Read ↗

Spesolimab for generalized pustular psoriasis: a prospective study with a 6-month follow-up.Semantic proximity Read ↗

Clinical advances in biological therapy for generalized pustular psoriasis: a review.Semantic proximity Read ↗

Pathophysiology of generalized pustular psoriasis.Semantic proximity Read ↗

Interleukin-36 promotes systemic Type-I IFN responses in severe psoriasis.Semantic proximity Read ↗

Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.Semantic proximity Read ↗

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation.Semantic proximity Read ↗

Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Two cases without mutations of IL36RN and CARD14 genes.Semantic proximity Read ↗

Case report: Successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations.Semantic proximity Read ↗

MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasisSemantic proximity Read ↗

Expression of interleukin-36 receptor antagonist in a patient with generalized pustular psoriasis harboring the p.Pro82Leu variant in the IL36RN gene.Semantic proximity Read ↗

Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: A PRISMA-compliant systematic review and meta-analysis.Semantic proximity Read ↗

Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.